Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Gives Kissei until July 21 to Report on Tavneos
Japan’s Ministry of Health, Labor and Welfare (MHLW) has given Kissei Pharmaceutical until July 21 to respond to an order requiring the company to report on concerns surrounding vasculitis drug Tavneos (avacopan), Health Minister Kenichiro Ueno said on July 3.…
To read the full story
Related Article
- NEJM Retracts Paper on Tavneos’ Pivotal Study
July 1, 2026
- Kissei Discussing Japan Response after EU Panel Recommends Pulling Tavneos Approval
June 29, 2026
- Panel Questions Timing of Tavneos Blue Letter Action
June 17, 2026
- MHLW to Continue Reviewing Tavneos Safety Measures: Official
June 10, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- MHLW Orders Detailed Report on Tavneos Efficacy Concerns
May 20, 2026
- Japan to Swiftly Consider Safety Measures over Tavneos: Minister
May 19, 2026
- Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
- Patient Group Pushes Emergency Steps to Address Concerta Supply Imbalances
May 18, 2026
REGULATORY
- Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
- MHLW Vaccine Panel Advances Mumps, RSV, HPV Discussions
July 23, 2026
- Japan Moves to Bar Duplicate IRB Reviews under Single-IRB Framework
July 23, 2026
- Chuikyo OKs NHI Listing for Cuorips’ iPSC-Based Riheart
July 23, 2026
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…